Trial of Spesolimab for Generalized Pustular Psoriasis
Journal
The New England journal of medicine
Journal Volume
385
Journal Issue
26
Pages
2431
Date Issued
2021
Author(s)
Bachelez, Hervé
Choon, Siew-Eng
Marrakchi, Slaheddine
Burden, A David
Morita, Akimichi
Navarini, Alexander A
Zheng, Min
et al.,
Abstract
Generalized pustular psoriasis (GPP) is a rare, life-threatening, inflammatory skin disease characterized by widespread eruption of sterile pustules. Interleukin-36 signaling is involved in the pathogenesis of this disorder. Spesolimab, a humanized anti-interleukin-36 receptor monoclonal antibody, is being studied for the treatment of GPP flares.
Subjects
JAPANESE PATIENTS; PLAQUE PSORIASIS; MUTATIONS; PROFILES; SYMPTOMS; EFFICACY; SAFETY
SDGs
Publisher
MASSACHUSETTS MEDICAL SOC
Type
journal article